Evaluation of Helicobacter pylori eradication and drug therapy in patients with functional dyspepsia

Zhao,Weidong; Zhong,Xiaoqin; Zhuang,Xinying; Ji,Hongmei; Li,Xinxin; Li,Anqing; Wang,Ruicai; Zhu,Jianyou; Li,Yanqing

doi:10.3892/etm.2013.1109

Evaluation of Helicobacter pylori eradication and drug therapy in patients with functional dyspepsia

Authors:
- Weidong Zhao
- Xiaoqin Zhong
- Xinying Zhuang
- Hongmei Ji
- Xinxin Li
- Anqing Li
- Ruicai Wang
- Jianyou Zhu
- Yanqing Li
View Affiliations

Affiliations: Department of Gastroenterology, Qilu Hospital, Shandong University, Jinan, Shandong 250012, P.R. China, Department of Gastroenterology, People's Hospital of Linzi District, Zibo, Shandong 255400, P.R. China, Department of Pathology, People's Hospital of Linzi District, Zibo, Shandong 255400, P.R. China
Published online on: May 13, 2013 https://doi.org/10.3892/etm.2013.1109
Pages: 37-44

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of this study was to assess the effect of Helicobactor pylori (H. pylori) infection and drug therapy on functional dyspepsia (FD) symptoms and gastrointestinal eosinophil count. In this study, 215 continuous FD patients fulfilling Rome Ⅲ criteria were enrolled. The patients were divided into a H. pylori-positive group and a H. pylori‑negative group. The H. pylori-positive group was divided into H. pylori‑eradicated and H. pylori-uneradicated groups following H. pylori-eradication treatment, and the H. pylori‑negative group was randomly divided into esomeprazole and teprenone treatment groups. The symptom scores of the esomeprazole group were significantly lower compared with those of the teprenone group at week 6 but not at baseline and week 2. Compared with the H. pylori-uneradicated group, eosinophil counts in the antrum and body were significantly reduced in the H. pylori-eradicated group at week 6. The number of gastric eosinophil clusters was significantly higher in the H. pylori-positive group than in the H. pylori-negative group. Eradication was associated with gastric eosinophil counts but did not affect duodenal eosinophil levels. Neither esomeprazole nor teprenone treatments reduced eosinophil levels in the stomach and duodenum of H. pylori‑negative patients.

View Figures

View References

1.	Geeraerts B and Tack J: Functional dyspepsia: past, present, and future. J Gastroenterol. 43:251–255. 2008. View Article : Google Scholar : PubMed/NCBI
2.	Mahadeva S and Goh KL: Epidemiology of functional dyspepsia: a global perspective. World J Gastroenterol. 12:2661–2666. 2006.PubMed/NCBI
3.	Talley NJ, Weaver AL and Zinsmeister AR: Impact of functional dyspepsia on quality of life. Dig Dis Sci. 40:584–589. 1995. View Article : Google Scholar : PubMed/NCBI
4.	Chang L: Review article: epidemiology and quality of life in functional gastrointestinal disorders. Aliment Pharmacol Ther. 7:31–39. 2004. View Article : Google Scholar : PubMed/NCBI
5.	Talley NJ: Functional gastrointestinal disorders as a public health problem. Neurogastroenterol Motil. 1:121–129. 2008. View Article : Google Scholar : PubMed/NCBI
6.	Powell N, Walker MM and Talley NJ: Gastrointestinal eosinophils in health, disease and functional disorders. Nat Rev Gastroenterol Hepatol. 7:146–156. 2010. View Article : Google Scholar : PubMed/NCBI
7.	Speirs RS, Speirs EE and Ponzio NM: A role for eosinophils in adaptive humoral immunity. Open Immunol J. 2:168–186. 2009. View Article : Google Scholar
8.	Stanghellini V, Tosetti C, Paternico A, Barbara G, Morselli-Labate AM, Monetti N, Marengo M and Corinaldesi R: Risk indicators of delayed gastric emptying of solids in patients with functional dyspepsia. Gastroenterology. 110:1036–1042. 1996. View Article : Google Scholar : PubMed/NCBI
9.	Sarnelli G, Caenepeel P, Geypens B, Janssens J and Tack J: Symptoms associated with impaired gastric emptying of solids and liquids in functional dyspepsia. Am J Gastroenterol. 98:783–788. 2003. View Article : Google Scholar : PubMed/NCBI
10.	Tack J, Piessevaux H, Coulie B, Caenepeel P and Janssens J: Role of impaired gastric accommodation to a meal in functional dyspepsia. Gastroenterology. 115:1346–1352. 1998. View Article : Google Scholar : PubMed/NCBI
11.	Tack J, Caenepeel P, Fischler B, Piessevaux H and Janssens J: Symptoms associated with hypersensitivity to gastric distention in functional dyspepsia. Gastroenterology. 121:526–535. 2001. View Article : Google Scholar : PubMed/NCBI
12.	Haug TT, Svebak S, Wilhelmsen I, Berstad A and Ursin H: Psychological factors and somatic symptoms in functional dyspepsia. A comparison with duodenal ulcer and healthy controls. J Psychosom Res. 38:281–291. 1994. View Article : Google Scholar : PubMed/NCBI
13.	Talley NJ, Walker MM, Aro P, Ronkainen J, Storskrubb T, Hindley LA, Harmsen WS, Zinsmeister AR and Agréus L: Non-ulcer dyspepsia and duodenal eosinophilia. An adult endoscopic population-based case-control study. Clin Gastroenterol Hepatol. 5:1175–1183. 2007. View Article : Google Scholar : PubMed/NCBI
14.	Rothenberg ME and Cohen MB: An eosinophil hypothesis for functional dyspepsia. Clin Gastroenterol Hepatol. 5:1147–1148. 2007. View Article : Google Scholar : PubMed/NCBI
15.	Gargala G, Lecleire S, François A, et al: Duodenal intraepithelial T lymphocytes in patients with functional dyspepsia. World J Gastroenterol. 13:2333–2338. 2007. View Article : Google Scholar : PubMed/NCBI
16.	Walker MM, Talley NJ, Prabhakar M, Pennaneac’h CJ, Aro P, Ronkainen J, Storskrubb T, Harmsen WS, Zinsmeister AR and Agreus L: Duodenal mastocytosis, eosinophilia and intraepithelial lymphocytosis as possible disease markers in the irritable bowel syndrome and functional dyspepsia. Aliment Pharmacol Ther. 29:765–773. 2009. View Article : Google Scholar
17.	Bischoff SC: Physiological and pathophysiological functions of intestinal mast cells. Semin Immunopathol. 31:185–205. 2009. View Article : Google Scholar : PubMed/NCBI
18.	Moayyedi P, Soo S, Deeks J, et al: Eradication of Helicobacter pylori for non-ulcer dyspepsia. Cochrane Database Sys Rev. 1:CD 0020962006.PubMed/NCBI
19.	Laine L, Schoenfeld P and Fennerty MB: Therapy for Helicobacter pylori in patients with nonulcer dyspepsia. A meta-analysis of randomized, controlled trials. Ann Intern Med. 134:361–369. 2001.
20.	Mönkemüller K and Malfertheiner P: Drug treatment of functional dyspepsia. World J Gastroenterol. 12:2694–2700. 2006.
21.	McNally MA and Talley NJ: Current treatments in functional dyspepsia. Curr Treat Options Gastroenterol. 10:157–168. 2007. View Article : Google Scholar : PubMed/NCBI
22.	Mazzoleni LE, Sander GB, Francesconi CF, et al: Helicobacter pylori eradication in functional dyspepsia: HEROES trial. Arch Intern Med. 171:1929–1936. 2011. View Article : Google Scholar : PubMed/NCBI
23.	von Arnim U, Peitz U, Vinson B, Gundermann KJ and Malfertheiner P: STW 5, a phytopharmacon for patients with functional dyspepsia: results of a multicenter, placebo-controlled double-blind study. Am J Gastroenterol. 102:1268–1275. 2007.PubMed/NCBI
24.	Tack J, Talley NJ, Camilleri M, Holtmann G, Hu P, Malagelada JR and Stanghellini V: Functional gastroduodenal disorders. Gastroenterology. 130:1466–1479. 2006. View Article : Google Scholar
25.	Talley N, Vakil NB and Moayyedi P: American gastroenterological association technical review on the evaluation of dyspepsia. Gastroenterology. 129:1756–1780. 2005. View Article : Google Scholar : PubMed/NCBI
26.	Talley NJ and Vakil N: Practice Parameters Committee of the American College of Gastroenterology: Guidelines for the management of dyspepsia. Am J Gastroenterol. 100:2324–2337. 2005. View Article : Google Scholar : PubMed/NCBI
27.	Laheij RJ, van Rossum LG, Verbeek AL and Jansen JB: Helicobacter pylori infection treatment of nonulcer dyspepsia: an analysis of meta-analyses. J Clin Gastroenterol. 36:315–320. 2003. View Article : Google Scholar
28.	de Artaza Varasa T, Valle Muñoz J, Pérez-Grueso MJ, García Vela A, Martín Escobedo R, Rodríguez Merlo R, Cuena Boy R and Carrobles Jiménez JM: Effect of Helicobacter pylori eradication on patients with functional dyspepsia. Rev Esp Enferm Dig. 100:532–539. 2008.(In Spanish).
29.	di Mario F, Stefani N, Bò ND, Rugge M, Pilotto A, Cavestro GM, Cavallaro LG, Franzé A and Leandro G: Natural course of functional dyspepsia after Helicobacter pylori eradication: a seven-year survey. Dig Dis Sci. 50:2286–2295. 2000.PubMed/NCBI
30.	Lee KJ and Tack J: Duodenal implications in the pathophysiology of functional dyspepsia. J Neurogastroenterol Motil. 16:251–257. 2010. View Article : Google Scholar : PubMed/NCBI
31.	Berczi L, Tamássy K, Fekete B and Kopper L: Eosinophils and mast cells in Helicobacter pylori infected gastric mucosa. Pathol Oncol Res. 2:229–236. 1996.
32.	Kikuchi T, Kato K, Ohara S, Sekine H, Arikawa T, Suzuki T, Noguchi K, Saito M, Saito Y, Nagura H, Toyota T and Shimosegawa T: The relationship between persistent secretion of RANTES and residual infiltration of eosinophils and memory T lymphocytes after Helicobacter pylori eradication. J Pathol. 192:243–250. 2000. View Article : Google Scholar : PubMed/NCBI
33.	Collen MJ and Loebenberg MJ: Basal gastric acid secretion in nonulcer dyspepsia with or without duodenitis. Dig Dis Sci. 34:246–250. 1989. View Article : Google Scholar : PubMed/NCBI
34.	George AA, Tsuchiyose M and Dooley CP: Sensitivity of the gastric mucosa to acid and duodenal contents in patients with nonulcer dyspepsia. Gastroenterology. 101:3–6. 1991.PubMed/NCBI
35.	Samsom M, Verhagen MA, vanBerge Henegouwen GP and Smout AJ: Abnormal clearance of exogenous acid and increased acid sensitivity of the proximal duodenum in dyspeptic patients. Gastroenterology. 116:515–520. 1999. View Article : Google Scholar : PubMed/NCBI
36.	di Stefano M, Vos R, Vanuytsel T, Janssens J and Tack J: Prolonged duodenal acid perfusion and dyspeptic symptom occurrence in healthy volunteers. Neurogastroenterol Motil. 21:e712–e740. 2009.PubMed/NCBI
37.	Lee KJ, Demarchi B, Demedts I, Sifrim D, Raeymaekers P and Tack J: A pilot study on duodenal acid exposure and its relationship to symptoms in functional dyspepsia with prominent nausea. Am J Gastroenterol. 99:1765–1773. 2004. View Article : Google Scholar : PubMed/NCBI
38.	Bratten J and Jones MP: Prolonged recording of duodenal acid exposure in patients with functional dyspepsia and controls using a radiotelemetry pH monitoring system. J Clin Gastroenterol. 43:527–533. 2009. View Article : Google Scholar : PubMed/NCBI
39.	Samsom M, Verhagen MA, van Berge Henegouwen GP and Smout AJ: Abnormal clearance of exogenous acid and increased acid sensitivity of the proximal duodenum in dyspeptic patients. Gastroenterology. 116:515–520. 1999. View Article : Google Scholar : PubMed/NCBI
40.	Hongo M, Harasawa S, Mine T, Sasaki I, Matsueda K, Kusano M, Hanyu N, Nakada K and Shibata C: Large-scale randomized clinical study on functional dyspepsia treatment with mosapride or teprenone: Japan Mosapride Mega-Study (JMMS). J Gastroenterol Hepatol. 27:62–68. 2012. View Article : Google Scholar : PubMed/NCBI